Format

Send to

Choose Destination
J Biol Chem. 2016 Dec 9;291(50):26164-26176. Epub 2016 Nov 1.

Identification of Anti-prion Compounds using a Novel Cellular Assay.

Author information

1
From the Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118.
2
the Department of Chemistry, Boston University, Boston, Massachusetts 02115, and.
3
the Laboratory for Drug Discovery in Neurodegeneration, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139.
4
From the Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118, daharris@bu.edu.

Abstract

Prion diseases are devastating neurodegenerative disorders with no known cure. One strategy for developing therapies for these diseases is to identify compounds that block conversion of the cellular form of the prion protein (PrPC) into the infectious isoform (PrPSc). Most previous efforts to discover such molecules by high-throughput screening methods have utilized, as a read-out, a single kind of cellular assay system: neuroblastoma cells that are persistently infected with scrapie prions. Here, we describe the use of an alternative cellular assay based on suppressing the spontaneous cytotoxicity of a mutant form of PrP (Δ105-125). Using this assay, we screened 75,000 compounds, and identified a group of phenethyl piperidines (exemplified by LD7), which reduces the accumulation of PrPSc in infected neuroblastoma cells by >90% at low micromolar doses, and inhibits PrPSc-induced synaptotoxicity in hippocampal neurons. By analyzing the structure-activity relationships of 35 chemical derivatives, we defined the pharmacophore of LD7, and identified a more potent derivative. Active compounds do not alter total or cell-surface levels of PrPC, and do not bind to recombinant PrP in surface plasmon resonance experiments, although at high concentrations they inhibit PrPSc-seeded conversion of recombinant PrP to a misfolded state in an in vitro reaction (RT-QuIC). This class of small molecules may provide valuable therapeutic leads, as well as chemical biological tools to identify cellular pathways underlying PrPSc metabolism and PrPC function.

KEYWORDS:

drug discovery; drug screening; neurodegeneration; neurological disease; prion; small molecule

PMID:
27803163
PMCID:
PMC5207084
DOI:
10.1074/jbc.M116.745612
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center